
From: Charles Kandziolka <charles.kandziolka@bayer.com>
Sent: Thursday, November 29, 2018 9:22 PM
To: AGO - High Cost Prescription Drugs
Subject: Vitrakvi® (larotrectinib)

Hello,

Pursuant to 18 V.S.A. § 4637, Bayer is notifying the Vermont Attorney General's Office that the introductory wholesale acquisition cost of Vitrakvi® (larotrectinib) is in excess of the Medicare Part D specialty drug threshold.

Product	NDC	WAC
Vitrakvi (larotrectinib) 25 mg Capsule	71777-390-01	\$ 10,933.33
Vitrakvi (larotrectinib) 100 mg Capsule	71777-391-01	\$ 32,800.00
Vitrakvi (larotrectinib) 20mg/mL Oral Solution	71777-392-01	\$ 14,577.78

Vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that:

- have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have no satisfactory alternative treatments or that have progressed following treatment.

More details about Vitrakvi will be provided in the 30-day reporting requirement.

Kind regards,

Charles Kandziolka
Strategic Pricing & Reimbursement

Bayer: Science For A Better Life

Bayer U.S. Market Access
100 Bayer Boulevard, PO Box 915
Building B200, 2B4234
Whippany, NJ 07981-0915, USA
Tel: (862) 404-4802
Mobile: (862) 812-9702
E-mail: charles.kandziolka@bayer.com